Whittle JR, Kriel J, Fatunla OE, Lu T, Moffet JJD, Spiteri M, Best SA, Freytag S. Spatial omics shed light on the tumour organisation of glioblastoma. Seminars in Cell and Developmental Biology. 2025;167:10.1016/j.semcdb.2024.12.006
Kay KE, Lee J, Hong ES, Beilis J, Dayal S, Wesley ER, Mitchell S, Wang SZ, Silver DJ, Volovetz J, Johnson S, McGraw M, Grabowski M, Lu T, Freytag L, Narayana VK, Freytag S, Best SA, Whittle JR, Wang Z, Reizes O, Yu JS, Hazen SL, Brown JM, Bayik D, Lathia J. Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition. Journal of Clinical Investigation. 2025;135(2):10.1172/jci177824
Lim-Fat MJ, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J, Bindra RS, Fangusaro J, Dhall G, Nicholson J, Jackson S, Davidson TB, Calaminus G, Robinson G, Whittle JR, Hau P, Ramaswamy V, Pajtler KW, Rudà R, Foreman NK, Hervey-Jumper SL, Das S, Dirks P, Bi WL, Huang A, Merchant TE, Fouladi M, Aldape K, Van den Bent MJ, Packer RJ, Miller JJ, Reardon DA, Chang SM, Haas-Kogan D, Tabori U, Hawkins C, Monje M, Wen PY, Bouffet E, Yeo KK. Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions. Neuro-Oncology. 2025;27(1):10.1093/neuonc/noae186
Schadewaldt V, O’Brien T, Kalla M, Krishnasamy M, Burns K, Bray SC, Gilbert C, De Abreu Lourenco R, Thomas J, Capurro D, Chapman W, Borda A, Dhillon RS, Whittle JR, Drummond KJ. Development of an evidence-informed implementation strategy for a digital supportive care platform for brain tumour patients, their carers and healthcare professionals. Digital Health. 2025;11:10.1177/20552076251316713
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2024;:10.1093/neuonc/noae259
Hitchen N, Shahnam A, Manoharan S, Topp M, Mileshkin L, Lim AM, Whittle JR, Luen SJ, Solomon B, Lackovic K, Desai J, Tran B. Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012–2022. Asia-Pacific Journal of Clinical Oncology. 2024;20(6):10.1111/ajco.14100
Whittle J, Rosenthal M, Spiteri M, Tobler R, Topp M, Cain S, Jones J, Shaya S, Valkovic A, Fatunla O, Dimou J, Roberts-Thomson S, McArdle D, Lui E, Nijagal B, Mitchell C, Grimmond S, Best S, Freytag S, Drummond K. CTNI-15. A PERIOPERATIVE STUDY OF SAFUSIDENIB IN PATIENTS WITH IDH1 MUTATED GLIOMA. Neuro-Oncology. 2024;26(Supplement_8):10.1093/neuonc/noae165.0382
Furst L, Roussel E, Leung R, George A, Li J, Best S, Whittle J, Cain J, Firestein R, Faux M, Eisenstat D. CNSC-36. REGULATION OF CELL FATE IN PAEDIATRIC HIGH-GRADE GLIOMA BY THE HOMEOBOX TRANSCRIPTION FACTOR DLX2. Neuro-Oncology. 2024;26(Supplement_8):10.1093/neuonc/noae165.0192
Cain SA, Topp M, Rosenthal M, Tobler R, Freytag S, Best SA, Whittle JR, Drummond KJ. A perioperative study of Safusidenib in patients with IDH1-mutated glioma. Future Oncology. 2024;20(33):10.1080/14796694.2024.2383064
Lu T, Freytag L, Moffet J, Kriel J, Whittle J, Freytag S, Best SA. OS07.5.A MULTI-MODAL EXAMINATION OF SPATIAL HETEROGENEITY IN THE ASTROCYTOMA MICROENVIRONMENT. Neuro-Oncology. 2024;26(Supplement_5):10.1093/neuonc/noae144.069
